Lifeward Partners with Shirley Ryan AbilityLab for ReWalk Exoskeleton Clinics
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy LFWD?
Lifeward announced a joint effort with Shirley Ryan AbilityLab. This collaboration will establish dedicated clinic days launching in the second quarter of 2026 at Shirley Ryan AbilityLab's Chicago campus to accelerate the evaluation and accessibility of the ReWalk Personal Exoskeleton.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFWD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFWD
Wall Street analysts forecast LFWD stock price to fall
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.780
Low
4.50
Averages
4.50
High
4.50
Current: 6.780
Low
4.50
Averages
4.50
High
4.50
About LFWD
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Lifeward Announces 1-for-12 Reverse Stock Split
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
See More
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
See More
Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026
- Leadership Transition: Lifeward announces the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating stability and strategic continuity during executive transitions.
- Financial Leadership Experience: Bob Marshall has been a board member and Chair of the Audit Committee since 2024, and his extensive financial leadership experience as CFO at Lantheus Holdings is expected to provide crucial support for Lifeward's strategic growth plans.
- Strategic Growth Plans: Lifeward's CEO Mark Grant emphasizes that Marshall's addition will enhance the company's innovation and development in medical technology, driving improvements in patient care and outcomes, thereby further solidifying its market position.
- Industry Background: Marshall's 16 years of experience at Zimmer Biomet Holdings will bring valuable industry insights to Lifeward, aiding the company in achieving sustainable growth in a competitive market.
See More
Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026
- Leadership Transition: Lifeward has announced the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating a strategic shift in the company's executive leadership.
- Experienced Successor: Bob Marshall has been a board member since 2024 and served as Chair of the Audit Committee, and his financial leadership and expertise in the healthcare public company sector are expected to significantly support Lifeward's strategic growth plans, enhancing its competitive edge in the medical technology field.
- Contribution of Predecessor: Joseph Turk's leadership has driven the company's development, and the board expressed gratitude for his contributions during his tenure, reflecting the company's commitment to leadership stability, which is crucial for maintaining investor confidence.
- Future Outlook: The appointment of the new chairman aligns with Lifeward's long-term strategic goals, aiming to improve patient care and outcomes through ongoing innovation and market expansion, thereby further solidifying its leadership position in the medical technology sector.
See More
Lifeward Partners with Verita Neuro to Expand ReWalk Market Access
- Market Expansion: Lifeward's international distribution agreement with Singapore's Verita Neuro aims to promote the ReWalk Personal Exoskeleton in Mexico, Thailand, and the UAE, potentially reaching over 25,000 spinal cord injury patients and significantly enhancing global market penetration.
- Innovative Delivery Model: The new agreement integrates ReWalk into Verita's multi-modal treatment protocols, with personalized setup and training in inpatient rehabilitation programs expected to accelerate clinical adoption and improve patient recovery outcomes.
- Market Potential: With over 7 million spinal cord injury survivors globally, Lifeward's total addressable market for ReWalk is estimated at $1.75 billion, indicating substantial growth potential in the medical technology sector.
- Strategic Alignment: This partnership complements Lifeward's existing distribution and reimbursement networks in the U.S. and Germany, aiming to drive long-term sustainable growth through a capital-efficient collaborative model that enhances the company's competitive edge in international markets.
See More
Lifeward Secures Humana Approval for ReWalk 7 Exoskeleton
- Market Leadership: Lifeward's approval from Humana Medicare Advantage Plan enables nearly half of all Medicare Advantage enrollees to access the ReWalk 7 exoskeleton, further solidifying its leadership position in the medical technology sector.
- Revenue Growth Potential: This approval is expected to enhance Lifeward's revenue and cash flow dynamics, thereby establishing a stronger foundation for sustainable growth in the U.S. market.
- Promotion of Innovative Technology: Humana's endorsement reflects its commitment to supporting innovative medical technologies aimed at providing more reliable exoskeleton solutions for spinal cord injury patients, thereby improving their quality of life.
- Accelerated Payer Adoption: As coverage for the ReWalk exoskeleton expands, Lifeward is experiencing a faster pace of prior authorization approvals, which not only increases reimbursement predictability but also creates favorable conditions for the company's future market expansion.
See More
Lifeward Announces 1-for-12 Reverse Stock Split
- Reverse Split Announcement: Lifeward has announced a 1-for-12 reverse stock split effective February 24, 2026, which will reduce outstanding shares from approximately 18.3 million to around 1.5 million, aimed at boosting the share price to comply with Nasdaq's $1.00 minimum bid requirement.
- Authorized Capital Increase: The board also approved increasing the authorized share capital to 100 million shares, providing greater flexibility for future financing and shareholder equity, despite the stock plummeting nearly 20% to an all-time low following the announcement.
- Historical Context: This marks Lifeward's second reverse split since March 2024, when a 1-for-7 split reduced outstanding shares from about 60.1 million to approximately 8.6 million, indicating ongoing adjustments in the company's capital management strategy.
- Partnership with Oramed: Lifeward has partnered with Oramed Pharmaceuticals to integrate its proprietary protein oral delivery technology, which could provide Lifeward with access to up to $47 million in capital, supporting future growth initiatives.
See More
Oramed Pharmaceuticals and Lifeward Sign Strategic Deal, Investing $9 Million
- Strategic Deal Signed: Oramed Pharmaceuticals and Lifeward have signed binding agreements involving the transfer of Oramed's Protein Oral Drug delivery technology, marking a significant advancement in innovative drug delivery.
- Equity Stake Increase: Oramed will obtain a 49.9% beneficial ownership interest in Lifeward upon satisfaction of certain terms, which is expected to significantly enhance its control and market influence over Lifeward.
- Financing Arrangement: Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, alongside an additional milestone-based $10 million note, further solidifying Oramed's financial involvement.
- Positive Market Reaction: In pre-market trading on NasdaqCM, Lifeward shares rose 21.5% to $0.77, reflecting positive market expectations and increased investor confidence regarding the transaction.
See More
Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026
- Leadership Transition: Lifeward announces the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating stability and strategic continuity during executive transitions.
- Financial Leadership Experience: Bob Marshall has been a board member and Chair of the Audit Committee since 2024, and his extensive financial leadership experience as CFO at Lantheus Holdings is expected to provide crucial support for Lifeward's strategic growth plans.
- Strategic Growth Plans: Lifeward's CEO Mark Grant emphasizes that Marshall's addition will enhance the company's innovation and development in medical technology, driving improvements in patient care and outcomes, thereby further solidifying its market position.
- Industry Background: Marshall's 16 years of experience at Zimmer Biomet Holdings will bring valuable industry insights to Lifeward, aiding the company in achieving sustainable growth in a competitive market.
See More
Lifeward Appoints Bob Marshall as Chairman of the Board Effective January 1, 2026
- Leadership Transition: Lifeward has announced the appointment of Bob Marshall as the new Chairman of the Board effective January 1, 2026, succeeding Joseph Turk, who will take on the role of CEO at Fresenius Medical Care, indicating a strategic shift in the company's executive leadership.
- Experienced Successor: Bob Marshall has been a board member since 2024 and served as Chair of the Audit Committee, and his financial leadership and expertise in the healthcare public company sector are expected to significantly support Lifeward's strategic growth plans, enhancing its competitive edge in the medical technology field.
- Contribution of Predecessor: Joseph Turk's leadership has driven the company's development, and the board expressed gratitude for his contributions during his tenure, reflecting the company's commitment to leadership stability, which is crucial for maintaining investor confidence.
- Future Outlook: The appointment of the new chairman aligns with Lifeward's long-term strategic goals, aiming to improve patient care and outcomes through ongoing innovation and market expansion, thereby further solidifying its leadership position in the medical technology sector.
See More
Lifeward Partners with Verita Neuro to Expand ReWalk Market Access
- Market Expansion: Lifeward's international distribution agreement with Singapore's Verita Neuro aims to promote the ReWalk Personal Exoskeleton in Mexico, Thailand, and the UAE, potentially reaching over 25,000 spinal cord injury patients and significantly enhancing global market penetration.
- Innovative Delivery Model: The new agreement integrates ReWalk into Verita's multi-modal treatment protocols, with personalized setup and training in inpatient rehabilitation programs expected to accelerate clinical adoption and improve patient recovery outcomes.
- Market Potential: With over 7 million spinal cord injury survivors globally, Lifeward's total addressable market for ReWalk is estimated at $1.75 billion, indicating substantial growth potential in the medical technology sector.
- Strategic Alignment: This partnership complements Lifeward's existing distribution and reimbursement networks in the U.S. and Germany, aiming to drive long-term sustainable growth through a capital-efficient collaborative model that enhances the company's competitive edge in international markets.
See More
Lifeward Secures Humana Approval for ReWalk 7 Exoskeleton
- Market Leadership: Lifeward's approval from Humana Medicare Advantage Plan enables nearly half of all Medicare Advantage enrollees to access the ReWalk 7 exoskeleton, further solidifying its leadership position in the medical technology sector.
- Revenue Growth Potential: This approval is expected to enhance Lifeward's revenue and cash flow dynamics, thereby establishing a stronger foundation for sustainable growth in the U.S. market.
- Promotion of Innovative Technology: Humana's endorsement reflects its commitment to supporting innovative medical technologies aimed at providing more reliable exoskeleton solutions for spinal cord injury patients, thereby improving their quality of life.
- Accelerated Payer Adoption: As coverage for the ReWalk exoskeleton expands, Lifeward is experiencing a faster pace of prior authorization approvals, which not only increases reimbursement predictability but also creates favorable conditions for the company's future market expansion.
See More
